Cryptococcal meningitis (CM) contributes up to 15% of HIV-related mortality and is the leading cause of HIV-related meningitis in many African LMICs. However, access to key commodities including the life-saving medicine, flucytosine, is poor in most resource-limited settings. This session will focus on the status of supply and demand work for cryptococcal meningitis and prepare the ground for new treatment strategies and new technologies. Key updates will be presented while the CDC will present a collaborative initiative to end deaths from crypto by 2030. The session will close with two top-level commitment roundtables.

Programme

Introduction
Co-chairs: Angela Loyse (St George’s University of London) & Amir Shroufi (CDC Foundation)

Where are we now? Perspectives from the Ministries of Health
Cordelia Katureebe (Ministry of Health: Uganda)

New trial findings: AMBITION-CM
Joe Jarvis (Botswana U-Penn Partnership)

Call to Action: End Cryptococcal Meningitis Deaths by 2030 Initiative
Tom Chiller (CDC)

Commitment & Action Roundtable – Programme Implementers
Moderator: Amir Shroufi (CDC Foundation)
James Conroy (CHAI)
Cordelia Katureebe (Ministry of Health: Uganda)
Apollinaire Tiam (EIPAF)
Gilles van Cutsem (MSF)
Zukiswa Pinini (National Department of Health: South Africa)

Commitment & Action Roundtable – Donors & UN Agencies
Moderator: Sharonann Lynch (Georgetown University)
Catherine Godfrey (PEPFAR)
Carmen Perez Casas (UNITAID)
Johanna Roth (EDCTP)
Shannon Hader (UNAIDS)
Nathan Ford (WHO)

Wrap-up: Carol Ruffell (DNDi-GARDP Southern Africa)